Skip to Content

Cellular Reprogramming Feats Keep Getting Better

August 28, 2008

Imagine if a piece of damaged heart muscle could be replaced with a simple chemical trick that triggered neighboring cells to convert themselves into whatever type of tissue was needed. Scientists at Harvard took a step closer to that possibility with a paper published today in the journal Nature. Doug Melton and his collaborators “transformed mouse pancreas cells that aid digestion into the insulin-producing cells that are destroyed in childhood diabetes, potentially giving stem cell scientists a powerful new way to one day grow replacement tissues for patients,” according to the Boston Globe.

The findings follow a whirlwind of new advances in cellular reprogramming, which include creating patient-specific stem-cell lines without the need for human eggs or embryos. The new research differs, however, in that one type of adult cell is converted directly into another type. The process doesn’t require that the cells first be transformed into undifferentiated cells before developing into the desired cell type.

According to the Washington Post,

Through a series of painstaking experiments involving mice, the Harvard biologists pinpointed three crucial molecular switches that, when flipped, completely convert a common cell in the pancreas into the more precious insulin-producing ones that diabetics need to survive.

“The feat … raises the tantalizing prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.

“It’s kind of an extreme makeover of a cell,” said Douglas A. Melton, co-director of the Harvard Stem Cell Institute, who led the research. “The goal is to create cells that are missing or defective in people. It’s very exciting.”

Melton and others caution that it’s likely to take years to translate the advance into useful treatments. From the Washington Post:

“It’s an important proof of concept,” said Lawrence Goldstein, a stem cell researcher at the University of California, San Diego. “But these things always look easier on the blackboard than when you have do [sic] them in actual patients.”

Although the experiment involved mice, Melton and other researchers were optimistic the approach would work in people.

“You never know for sure–mice aren’t humans,” [Harvard stem-cell biologist George] Daley said. “But the biology of pancreative [sic] development is very closely related in mice and humans.”

Melton has already started experimenting with human cells in the laboratory and hopes to start planning the first studies involving people with diabetes within a year. “I would say within five years we could be ready to start human trials,” Melton said.

Keep Reading

Most Popular

Workers disinfect the street outside Shijiazhuang Railway Station
Workers disinfect the street outside Shijiazhuang Railway Station

Why China is still obsessed with disinfecting everything

Most public health bodies dealing with covid have long since moved on from the idea of surface transmission. China’s didn’t—and that helps it control the narrative about the disease’s origins and danger.

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.